TrialDrug design, development and therapy2014

Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects.

Yu-Jung Cha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.